Explore 3 Stock Ideas & Industry Insights Download Free Report

Elevation Oncology Inc

Company price
None USD 0.00(0%)
Last update at 2025-08-21T20:04:48.798413Z
Market Cap
207.08M

Momentum Score

…

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.36
Low
5.83
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.36
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.55
ROE
-71.82%
Net Debt
-19.12M
ROCE
-111.34%
Diluted EPS TTM
-0.85

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -95.06M -32.04M -17.27M -
Net income -95.08M -32.04M -17.27M -
Selling general administrative 15.83M 8.45M 1.80M -
Reconciled depreciation 0.03M 0.02M 0.01M -
Ebit -94.58M -32.05M -17.28M -3.57M
Ebitda -94.55M -32.03M -17.26M -
Depreciation and amortization 0.03M 0.02M 0.01M -
Non operating income net other -0.51M - - -
Operating income -94.55M -32.05M -17.28M -
Other operating expenses 94.55M 32.05M 17.28M -
Interest expense 0.48M 0.01M 0.00M 0.00M
Tax provision 0.03M - - -
Income tax expense 0.03M -0.01M -0.01M -
Total revenue 0.00M 0.00M 0.00M -
Total operating expenses 94.55M 32.05M 17.28M -
Total other income expense net -0.51M 0.01M 0.01M -
Net income from continuing ops -95.08M -32.04M -17.27M -
Net income applicable to common shares -95.08M -32.04M -17.27M -8.82M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 89.09M 94.16M 149.49M 80.91M 1.91M
Intangible assets 0.00M - - - -
Other current assets 4.86M 2.70M 3.14M 1.39M 0.17M
Total liab 34.28M 45.13M 8.80M 103.99M 7.79M
Total stockholder equity 54.81M 49.03M 140.70M -23.08M -5.87M
Other current liab 3.64M 9.33M 3.14M 1.11M 0.14M
Common stock 0.00M 0.00M 0.00M - -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -195.97M -150.27M -55.19M -23.15M -5.88M
Other liab - 0.00M 0.01M 0.01M -
Other assets 0.00M 1.09M 0.03M 0.07M -
Cash 49.26M 45.92M 146.28M 79.40M 1.74M
Total current liabilities 4.14M 15.69M 8.79M 6.79M 0.60M
Net debt -19.12M -16.48M -146.28M -79.40M -1.74M
Short long term debt total 30.14M 29.43M - - -
Other stockholder equity 250.77M 105.30M 195.88M 0.07M 0.01M
Property plant equipment - 0.10M 0.04M - -
Total current assets 87.96M 92.98M 149.42M 80.79M 1.91M
Net tangible assets - 49.03M 140.70M -23.14M -5.87M
Short term investments 33.85M 44.36M - - -
Long term debt 30.14M 29.43M - - -
Accounts payable 0.51M 6.36M 5.65M 5.68M 0.46M
Accumulated other comprehensive income 0.01M -0.16M -149.49M -0.01M -
Common stock total equity - 0.00M - - -
Retained earnings total equity - -150.27M - - -
Non currrent assets other 1.07M 1.09M 0.03M 0.07M -
Non current assets total 1.13M 1.18M 0.07M 0.12M 0.00M
Long term debt total - 29.43M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -44.31M -44.31M -0.07M -44.31M
Change to liabilities 6.90M -0.03M 5.22M 0.69M
Total cashflows from investing activities -44.40M -44.40M -0.07M -0.07M
Net borrowings 29.53M 30.00M 30.00M 30.00M
Total cash from financing activities 29.51M 97.05M 90.03M 10.79M
Change to operating activities 5.58M 0.31M -0.32M -0.06M
Net income -95.08M -32.04M -17.27M -8.82M
Change in cash -100.37M 66.88M 77.66M 2.61M
Begin period cash flow 146.28M 79.40M 1.74M -
End period cash flow 45.92M 146.28M 79.40M 1.74M
Total cash from operating activities -85.48M -30.17M -12.30M -8.18M
Issuance of capital stock 0.00M 97.06M 90.20M -
Depreciation 0.03M 0.02M 0.01M 0.02M
Sale purchase of stock -0.04M - - -
Other cashflows from financing activities 30.00M -0.01M 90.01M -0.12M
Change to netincome 3.49M 1.57M 0.05M 0.01M
Capital expenditures 0.09M 0.09M 0.07M 0.07M
Cash flows other operating -0.61M - - -
Cash and cash equivalents changes -100.37M - - -
Change in working capital 6.29M 0.28M 4.90M -
Stock based compensation 3.21M 1.57M 0.05M -
Other non cash items 0.07M -66.35M - -
Free cash flow -85.57M -30.17M -12.37M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Elevation Oncology Inc

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

101 Federal Street, Boston, MA, United States, 02110

716 371 1125

29

Name Title Year Born
Dr. Shawn M. Leland Pharm.D., R.Ph. Founder, Pres, CEO & Director 1984
Mr. Joseph J. Ferra Jr. Chief Financial Officer 1976
Ms. Valerie Malyvanh Jansen M.D., Ph.D. Chief Medical Officer 1978
Ms. Tammy Furlong CPA, P.M.P. VP of Fin. & Accounting and Sec. NA
Dr. David Dornan Ph.D. Chief Scientific Officer 1978
Candice Masse Sr. Director of Corp. Communications & Investor Relations NA
Mr. Robert C. Yang VP of Legal Affairs NA
Mr. Brian Sullivan VP of Corp. Devel. NA
Mr. Ryan Bloomer Head of CMC NA
Mr. Joseph J. Ferra Jr. CEO, President & Director 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…